Evidence map›Paper›PMID 32631303›Full record

ArticleBMC pulmonary medicine2020

Rapid disease progress in a PVOD patient carrying a novel EIF

Xiaofang Zeng, Fan Chen, Anandharajan Rathinasabapathy, Tangzhiming Li, Agila Adnan Ali Mohammed Mohammed, Zaixin Yu

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC pulmonary medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Molecular genetics of pulmonary hypertension in children.Current opinion in genetics & development · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Xiaofang ZengDepartment of Cardiology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
Fan ChenDepartment of Cardiology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
Anandharajan RathinasabapathyDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Tangzhiming LiDepartment of Cardiology, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, 1017 Dongmen North Road, Shenzhen, Guangdong, China.
Agila Adnan Ali Mohammed MohammedDepartment of Cardiology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China.
Zaixin YuDepartment of Cardiology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008, Hunan, China. yuzaixin@126.com.
Central South University · CNXiangya Hospital Central South University · CNJinan University · CNVanderbilt University Medical Center · US

Funding

Major national science and technology projects grant No.SQ2017ZX090304019the National Natural Science Foundation of China grant No. 81873416
6 · The paper itself

Abstract

backgroundPulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH) share an overlapping disease phenotype. Hence it is necessary to distinguish them. CASE PRESENTATION: Our 14-year-old female patient admitted with progressive shortness of breath, dizziness, and fatigue even after minimal physical activity was clinically suspected for PAH, based on her previous history. Her chest computed tomography artery reported the presence of PVOD triad features - subpleural thickened septal lines, ground-glass nodules/opacities and mediastinal lymphadenopathy. Because of her weak physical stature, a lung biopsy was not performed; however, the genetic testing identified a novel heterozygous EIF2AK4 mutation at c.4833_4836dup (p.Q1613Kfs*10) - the dominant susceptible factor driving PVOD. Combination of genetic testing and computed tomography artery facilitated us to distinguish PVOD from PAH. Her disease symptoms advanced aggressively so that she died even before the lung transplantation, which was less than 6 months from the onset of disease symptoms.

conclusionThis case report highlights that novel EIF2AK4 mutation at [c.4833_4836dup (p.Q1613Kfs*10)] would predict an aggressive phenotype of PVOD. Hence, we conclude that a genetic test identifying EIF2AK4 mutation would serve as a tool for the early diagnosis of PVOD, circumventing lung biopsy.

Indexed as

AdolescentDiagnosis, DifferentialDisease ProgressionFatal OutcomeFemaleHumansMutationPhenotypeProtein Serine-Threonine KinasesPulmonary Arterial HypertensionPulmonary Veno-Occlusive DiseaseTomography, X-Ray ComputedEIF2AK4 protein, humanProtein Serine-Threonine KinasesCase reportEIF2AK4Pulmonary hypertensionPulmonary veno-occlusive disease

Identifiers

PMID32631303
PMCPMC7336641
OpenAlexW3040308890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.